NOTE: Divergence has been acquired by Monsanto Company. Some information on this website may no longer be up-to-date.
Please contact us for more information.
Divergence is a science-based company
that has successfully pioneered multiple approaches to the discovery of safe and effective products for
the control of infectious agents in agriculture and medicine.
Our platform in genomics and RNA interference is described here.
Details of our Harvest™ platform for small molecule agrochemical
discovery and STEM™ platform for the development of plant biotechnology
traits have not yet been publicly disclosed. Divergence has established a reputation for scientific
excellence including 19 issued patents and numerous pending applications,
publication of more than 40 peer-reviewed original research and review papers,
and receipt of more than 25 grants.
Genomics and RNAi
Divergence is a leader in the application of comparative and functional genomics, including RNAi, to the control of parasitic nematodes.
Harvest™
A Divergence proprietary platform technology with broad utility in the development of agrochemicals
including nematicides, fungicides, insecticides, and herbicides.
STEM™
A Divergence proprietary platform technology with broad utility in the development of unique traits
for plant biotechnology.
Assay Systems
Divergence focuses on rapid movement from concept to advanced R&D. Divergence has implemented
proprietary assays to quickly determine the pest-control efficacy of candidate molecules and genes.
Publications
Divergence has established a reputation for scientific excellence including publication of over
40 peer-reviewed original research and review papers.
Patents
Divergence has 19 issued patents and multiple patents pending in the United States and
internationally.
